Brandt-Jürgens Jan, Rudwaleit Martin, Behrens Frank, Ritchlin Christopher, Peterlik Daniel, Quebe-Fehling Erhard, Deodhar Atul
Rheumatologische Schwerpunktpraxis, Bundesallee 104/105, 12161 Berlin, Germany.
Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, University of Bielefeld, Bielefeld, Germany.
Ther Adv Musculoskelet Dis. 2025 Jun 6;17:1759720X251340255. doi: 10.1177/1759720X251340255. eCollection 2025.
The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported.
To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies.
This was a post hoc analysis from 11 phase III studies.
Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed.
In the axSpA cohort ( = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort ( = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm.
During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.
先前已报道了接受司库奇尤单抗治疗的中轴型脊柱关节炎（axSpA）患者葡萄膜炎的发病率。
在安慰剂对照的III期研究中，评估接受司库奇尤单抗或安慰剂治疗的axSpA和银屑病关节炎（PsA）患者葡萄膜炎的发病率。
这是一项对11项III期研究的事后分析。
分析来自axSpA（MEASURE 1 - 5和PREVENT研究）和PsA（FUTURE 1 - 5研究）的汇总数据。
在axSpA队列（n = 1980）中，司库奇尤单抗150 mg组葡萄膜炎的发病率为每100患者年1.29例，安慰剂组为每100患者年1.72例。在PsA队列（n = 2453）中，司库奇尤单抗300 mg组葡萄膜炎的发病率为每100患者年0.71例；安慰剂组未报告任何事件。
在安慰剂对照阶段，接受司库奇尤单抗治疗的axSpA患者中葡萄膜炎的发病率在数值上较低。在PsA患者中，接受司库奇尤单抗治疗的患者发病率较低，而安慰剂组未报告葡萄膜炎。
